Clinical Trial Update: Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 safety and efficacy trial of OMS721 in patients with atypical hemolytic uremic syndrome has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome
• Thrombotic Microangiopathy

Drugs mentioned

• OMS721 (narsoplimab)

Snippet

Sponsor: Omeros Corporation | Conditions: Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2025-12-10